Trial Profile
A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jan 2018
Price :
$35
*
At a glance
- Drugs Amlodipine/olmesartan-medoxomil/rosuvastatin (Primary)
- Indications Hyperlipidaemia; Hypertension
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
- 15 Feb 2016 New trial record